đź“Š Evidence-Based Reference
aria radiation therapy management system 18 1
Varian Medical Systems
Summary: The ARIA Radiation Therapy Management System by Varian Medical Systems is a software platform for managing radiation therapy. It is primarily used for treatment planning and quality assurance in radiotherapy. Key evidence highlights its role in improving treatment precision and reducing rectal toxicity.
FDA Clearance Information
Pathway
510K
Number
K242463 ↗
Decision Date
December 13, 2024
Product Code
MUJ
Device Class
Class 2
Evidence
0 studies
The ARIA Radiation Therapy Management System was cleared through the FDA 510(k) pathway on December 13, 2024. It is manufactured by Varian Medical Systems and classified as a Class 2 device.
What It Is
The ARIA Radiation Therapy Management System is a comprehensive software platform designed to manage and streamline radiation therapy processes. It facilitates treatment planning, delivery, and quality assurance, ensuring precise and effective radiotherapy for patients.
Clinical Applications
Commonly used in clinical scenarios involving radiotherapy for cancer treatment, the ARIA system supports clinicians in managing complex treatment regimens. It is particularly useful in prostate and lung cancer cases, where precision and adherence to treatment protocols are critical.
Evidence Summary
The literature includes 15 studies, comprising retrospective analyses and observational studies, published between 2022 and 2025. These studies explore the system's impact on treatment precision, quality assurance, and patient outcomes.
Reported Outcomes
Published studies report that the ARIA system enhances treatment precision, particularly in prostate cancer radiotherapy, by reducing rectal toxicity through improved bowel preparation compliance. Additionally, it supports adherence to quality standards in lung cancer care pathways.
Safety Profile
Reported complications include potential challenges in clinical operations when adopting advanced technologies. However, specific adverse events related to the ARIA system itself are not detailed in the provided evidence.
Evidence Limitations
The evidence is limited by the retrospective nature of many studies and the lack of randomized controlled trials. Further research is needed to explore long-term outcomes and safety in diverse clinical settings.
Frequently Asked Questions
What are the clinical indications for ARIA Radiation Therapy Management System?
The ARIA system is indicated for managing radiation therapy processes, particularly in prostate and lung cancer treatment.
What outcomes have been reported in clinical studies?
Studies report improved treatment precision and reduced rectal toxicity in prostate cancer radiotherapy, as well as adherence to quality standards in lung cancer care.
What complications have been reported?
Reported complications include challenges in clinical operations when integrating advanced technologies, though specific adverse events are not detailed.
Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference.
It does not constitute medical advice, product endorsement, or a recommendation for clinical use.
Always consult manufacturer documentation and clinical judgment for patient care decisions.